Wedbush Weighs in on argenx’s Q1 Earnings (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGX) – Equities research analysts at Wedbush lifted their Q1 2025 EPS estimates for argenx in a research note issued to investors on Thursday, October 31st. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of $1.91 per share for the quarter, up from their prior estimate of $1.83. Wedbush has a “Outperform” rating and a $560.00 price target on the stock. The consensus estimate for argenx’s current full-year earnings is ($0.36) per share. Wedbush also issued estimates for argenx’s Q2 2025 earnings at $2.23 EPS and Q3 2025 earnings at $2.62 EPS.

Several other analysts have also issued reports on the stock. Piper Sandler boosted their price objective on shares of argenx from $553.00 to $620.00 and gave the company an “overweight” rating in a report on Friday. JMP Securities upped their price objective on shares of argenx from $497.00 to $606.00 and gave the stock a “market outperform” rating in a report on Friday. JPMorgan Chase & Co. increased their price objective on shares of argenx from $500.00 to $640.00 and gave the stock an “overweight” rating in a research report on Friday, August 23rd. Evercore ISI boosted their target price on argenx from $478.00 to $533.00 and gave the company an “outperform” rating in a research report on Friday, July 12th. Finally, Oppenheimer raised their price target on argenx from $560.00 to $646.00 and gave the stock an “outperform” rating in a research report on Friday. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $596.78.

argenx Stock Up 1.6 %

NASDAQ:ARGX opened at $595.58 on Monday. argenx has a 52 week low of $327.73 and a 52 week high of $610.73. The stock’s fifty day moving average is $539.46 and its two-hundred day moving average is $466.48. The company has a market capitalization of $35.62 billion, a P/E ratio of -676.80 and a beta of 0.61.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $0.10 by $1.29. The company had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 0.96%. During the same period in the previous year, the business posted ($1.25) EPS.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Blue Trust Inc. increased its stake in argenx by 620.0% in the second quarter. Blue Trust Inc. now owns 72 shares of the company’s stock valued at $28,000 after purchasing an additional 62 shares during the last quarter. J.Safra Asset Management Corp boosted its holdings in shares of argenx by 590.0% in the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock valued at $30,000 after buying an additional 59 shares in the last quarter. GAMMA Investing LLC grew its position in shares of argenx by 51.3% in the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after buying an additional 40 shares during the last quarter. Point72 Hong Kong Ltd acquired a new stake in argenx during the 2nd quarter worth $76,000. Finally, Cromwell Holdings LLC raised its stake in argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after acquiring an additional 66 shares in the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.